Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 3,708 matching trials from the live ClinicalTrials.gov search.
Conditions
Hodgkin Lymphoma
Interventions
Pembrolizumab, Involved Site Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Not listed No phase listed Observational

APPEND-CT Registry

NCT06213285
Conditions
Stroke, Ischemic, Device Related Thrombosis, Atrial Fibrillation
Interventions
Watchman FLX left atrial appendage occlusion
Device
Lead sponsor
Aarhus University Hospital
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Cardiac Output, Sedation
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Month to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Prostate Cancer
Interventions
123I-MIP-1072
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Phase 4 Interventional Results available

Inpatient Clinical Trial of NAC

NCT03581084
Conditions
Asthma
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Nodule Solitary Pulmonary, Non-small Cell Lung Cancer
Interventions
Guardant Health ct-DNA LUNAR assay
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
1,440 participants
Timeline
2017 – 2030
U.S. locations
3
States / cities
San Francisco, California
Conditions
Cancer of Head and Neck
Interventions
Soy isoflavone, Radiation, Cisplatin
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Hypopharyngeal Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Laryngeal Cancer, Recurrent Lip and Oral Cavity Cancer, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Nasopharyngeal Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Oropharyngeal Cancer, Recurrent Pancreatic Cancer, Recurrent Paranasal Sinus and Nasal Cavity Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Colon Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer, Tongue Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
Drug
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Stanford, California
Conditions
Lung Cancer, Metastatic Cancer
Interventions
cryosurgery, positron emission tomography
Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Prostate Cancer
Interventions
99mTc-MIP-1404 Injection, Whole-Body Planar and pelvic SPECT/CT scan
Drug · Diagnostic Test
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 26 more
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Iodine (124I) Girentuximab
Drug
Lead sponsor
Heidelberg Pharma AG
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Los Angeles, California • Tampa, Florida • Burlington, Massachusetts + 5 more
Conditions
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan
Biological · Procedure · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Terminated Not applicable Interventional Results available

Trial Comparing PLA to HIGRT (PROVE-HCC)

NCT03402607
Conditions
Hepatocellular Carcinoma
Interventions
Percutaneous Local Ablation, Hypofractionated Image Guided Radiation Therapy
Procedure · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Durham, North Carolina
Conditions
Prostate Cancer
Interventions
99mTc-MIP-1404
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational

High Image Matrix CT Reconstruction

NCT02610465
Conditions
Healthy Subjects, Pulmonary-Related Conditions, Cardiac-Related Conditions
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Interventions
PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
Diagnostic Test · Drug · Radiation
Lead sponsor
Martin T. King, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts
Conditions
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer, Stage III Lung Cancer
Interventions
Cisplatin, Carboplatin, Etoposide, Pembrolizumab, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Radiation Therapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Malignant Neoplasm of Breast TNM Staging Distant Metastasis (M), Untreated Bone Metastases
Interventions
NaF PET/MRI, NaF PET/CT, FDG PET/CT
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
Interventions
Intensity Modulated Radiation Therapy, Carboplatin, MD Anderson Symptom Inventory (MDASI)-Plus module, EuroQol (EQ-5D), SF-12, MOS Social Support Measure, CES-D, Blood for ctDNA (optional), Blood for SCCA, Paclitaxel
Radiation · Drug · Other + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Breast Cancer
Interventions
MammaPrint 70-gene expression profile, BluePrint 80 gene expression profile
Other
Lead sponsor
Agendia
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
1,142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
76
States / cities
Glendale, Arizona • Scottsdale, Arizona • Berkeley, California + 67 more
Conditions
Head and Neck Carcinoma
Interventions
Bioelectric Impedance Analysis, Computed Tomography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Perfusion
Interventions
Dual Energy CT
Procedure
Lead sponsor
Sameer Avasarala
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Withdrawn Not applicable Interventional

MRI Adaptive Replanning Using ViewRay

NCT02950792
Conditions
Non-Small Cell Lung Cancer
Interventions
ViewRay MRI, Stereotactic Body Radiation Therapy Boost
Device · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida